Logo image of WENA

ANEW MEDICAL INC (WENA) Stock Fundamental Analysis

NASDAQ:WENA - Nasdaq - US7580831094 - Common Stock - Currency: USD

0.726  0 (-0.55%)

After market: 0.755 +0.03 (+3.99%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to WENA. WENA was compared to 101 industry peers in the Financial Services industry. WENA may be in some trouble as it scores bad on both profitability and health. WENA has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

WENA had negative earnings in the past year.
In the past year WENA has reported a negative cash flow from operations.
WENA Yearly Net Income VS EBIT VS OCF VS FCFWENA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 0 500K -500K 1M -1M

1.2 Ratios

WENA has a worse Return On Assets (-22.50%) than 90.29% of its industry peers.
Industry RankSector Rank
ROA -22.5%
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
WENA Yearly ROA, ROE, ROICWENA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 0 5 -5 10

1.3 Margins

WENA does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
WENA Yearly Profit, Operating, Gross MarginsWENA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023

More info and screens

2

2. Health

2.1 Basic Checks

Compared to 1 year ago, WENA has less shares outstanding
The debt/assets ratio for WENA is higher compared to a year ago.
WENA Yearly Shares OutstandingWENA Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 5M 10M
WENA Yearly Total Debt VS Total AssetsWENA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 20M 40M 60M 80M 100M

2.2 Solvency

WENA has an Altman-Z score of -2.38. This is a bad value and indicates that WENA is not financially healthy and even has some risk of bankruptcy.
WENA's Altman-Z score of -2.38 is on the low side compared to the rest of the industry. WENA is outperformed by 75.73% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -2.38
ROIC/WACCN/A
WACCN/A
WENA Yearly LT Debt VS Equity VS FCFWENA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 0 20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 1.11 indicates that WENA should not have too much problems paying its short term obligations.
The Current ratio of WENA (1.11) is comparable to the rest of the industry.
WENA has a Quick Ratio of 1.11. This is a normal value and indicates that WENA is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.11, WENA is in line with its industry, outperforming 57.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.11
Quick Ratio 1.11
WENA Yearly Current Assets VS Current LiabilitesWENA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 500K 1M 1.5M 2M

More info and screens

0

3. Growth

3.1 Past

WENA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -115.92%.
EPS 1Y (TTM)-115.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.05%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
WENA Yearly Revenue VS EstimatesWENA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023
WENA Yearly EPS VS EstimatesWENA Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for WENA. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
WENA Price Earnings VS Forward Price EarningsWENA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
WENA Per share dataWENA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.05 -0.1 -0.15 -0.2 -0.25

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for WENA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ANEW MEDICAL INC

NASDAQ:WENA (9/16/2024, 8:00:02 PM)

After market: 0.755 +0.03 (+3.99%)

0.726

0 (-0.55%)

Chartmill FA Rating
GICS SectorFinancials
GICS IndustryGroupFinancial Services
GICS IndustryFinancial Services
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst Owners3.59%
Inst Owner Change0%
Ins Owners8.49%
Ins Owner Change0%
Market Cap10.98M
AnalystsN/A
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.03
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.09
FCFYN/A
OCF(TTM)-0.09
OCFYN/A
SpS0
BVpS-0.1
TBVpS-0.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -22.5%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.11
Quick Ratio 1.11
Altman-Z -2.38
F-Score2
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-115.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-44.05%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-29.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-157.69%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-157.69%
OCF growth 3YN/A
OCF growth 5YN/A